A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

NCT00586924 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Hairy Cell Leukemia

Interventions

DRUG: Moxetumomab Pasudotox (CAT 8015)
DRUG: Moxetumomab Pasudotox (CAT 8015)
DRUG: Moxetumomab Pasudotox (CAT 8015)
DRUG: Moxetumomab Pasudotox (CAT 8015)
DRUG: CAT 8015 (Moxetumomab Pasudotox)
DRUG: Moxetumomab Pasudotox (CAT 8015)

Sponsor

MedImmune LLC

Collaborators

[object Object]